Galecto Inc

NASDAQ:GLTO   3:59:50 PM EDT
2.28
+0.04 (+1.79%)
Other Pre-Announcement

Galecto Provides Enrollment Update On Phase 2A Mylox-1 Trial And Reiterates Expected Timing Of Multiple Data Readouts In 2022

Published: 12/20/2021 13:33 GMT
Galecto Inc (GLTO) - Galecto Provides Enrollment Update on Phase 2a Mylox-1 Trial and Reiterates Expected Timing of Multiple Data Readouts in 2022.
Galecto Inc - Enrolled 10 of Anticipated 16 Patients in Its Phase 2a Trial of Its Oral Loxl2 Inhibitor Gb2064 in Myelofibrosis.
Galecto Inc - Also Anticipate Reporting Topline Data From Part 2 of Our Liver Cirrhosis Gulliver-2 Trial Next Year.